Corcept Therapeutics

YTD

ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.

CEO

Joseph K. Belanoff

CEOJoseph K. Belanoff

Employees

730

Employees730

Headquarters

Redwood City, California

HeadquartersRedwood City, California

Founded

1998

Founded1998

Employees

730

Employees730

CORT Key Statistics

Market cap

8.46B

Market cap8.46B

Price-Earnings ratio

64.66

Price-Earnings ratio64.66

Dividend yield

—

Dividend yield—

Average volume

1.40M

Average volume1.40M

High today

$84.98

High today$84.98

Low today

$71.29

Low today$71.29

Open price

$84.46

Open price$84.46

Volume

1.35M

Volume1.35M

52 Week high

$126.38

52 Week high$126.38

52 Week low

$28.66

52 Week low$28.66

Stock Snapshot

Corcept Therapeutics(CORT) stock is priced at $78.28, giving the company a market capitalization of 8.46B. It carries a P/E multiple of 64.66.

On 2026-11-04, Corcept Therapeutics(CORT) stock moved within a range of $71.29 to $84.98. With shares now at $78.28, the stock is trading +9.8% above its intraday low and -7.9% below the session's peak.

Trading volume for Corcept Therapeutics(CORT) stock has reached 1.35M, versus its average volume of 1.4M.

The stock's 52-week range extends from a low of $28.66 to a high of $126.38.

CORT News

Simply Wall St 17h

Is Corcept Therapeutics Cheap After Strong Earnings And BELLA Trial Results?

Corcept Therapeutics (CORT) just paired a sharp step-up in profitability with fresh clinical data. Third quarter net income reached US$126.78 million, helped by...

Zacks 21h

Corcept Therapeutics Q3 Earnings and Revenues Surpass Estimates

Corcept Therapeutics (CORT Quick QuoteCORT - Free Report) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0....

TipRanks 21h

Corcept Therapeutics Reports Strong Third-Quarter Revenue and Earnings Growth

The latest announcement is out from Corcept Therapeutics ( (CORT) ). On November 3, 2026, Corcept reported third-quarter revenue of $340.5 million, up 64% from...

Analyst ratings

71%

of 7 ratings

Buy

71.4%

Hold

14.3%

Sell

14.3%

More CORT News

Simply Wall St 6d

How Positive Ovarian Cancer Trial Data Will Impact Corcept Therapeutics Stock

Corcept Therapeutics reported positive Part A data from its Phase 2 BELLA trial in platinum-resistant ovarian cancer, where adding Lifyorli and bevacizumab to n...

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Broadcom

Robinhood Markets

Palantir Technologies

Novo Nordisk

Taiwan Semiconductor Manu…

Palo Alto Networks

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.